Immunotherapy Coverage from Every Angle

Recent News

Patterns of PD-L1 Expression in NSCLC Harboring Driver Oncogene Mutations
Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC
Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma
Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer
Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?
Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma
Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?
Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma
Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy
Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results
Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer
First-in-Human Trial of Bispecific IgG4 Antibody for Multiple Myeloma
Enfortumab Vedotin-ejfv Receives FDA Approval for Advanced Urothelial Carcinoma
Pooled Analysis of HER2-Targeting Antibody-Drug Conjugate in Metastatic Breast Cancer
FDA Approves Daratumumab and Hyaluronidase-fihj Combination Therapy for Multiple Myeloma
Perioperative Use of Cemiplimab Under Study in Cutaneous Squamous Cell Carcinoma
Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer
Phase II Study of Bipolar Androgen Therapy and Nivolumab in Prostate Cancer
EHA2021: ANDROMEDA Trial Update Supports Daratumumab-Based Therapy for AL Amyloidosis
FDA Expands Pembrolizumab Label for Locally Advanced Cutaneous Squamous Cell Carcinoma
Early Results With PSMA-Targeting T-Cell Engager in Metastatic Prostate Cancer
EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab
ASCO2021: CARTITUDE-1 Update on Ciltacabtagene Autoleucel for Resistant Myeloma
Does Pembrolizumab Plus Chemotherapy–Induced Pneumonitis Impact Survival Outcomes in NSCLC?
Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital
ASCO 2021: Converting Peripheral Blood Mononuclear Cells Into Autologous Cellular Therapy for CLL
ASCO 2021: Phase II Study of Domatinostat Plus Avelumab for Merkel Cell Carcinoma
ASCO 2021: LAG-3 Protein Plus Pembrolizumab Under Study in Metastatic Lung Cancer
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: Changing the Treatment Game
ASCO 2021: Early Trial Update of Teclistamab in Resistant Multiple Myeloma
EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab
FDA Brief: Teclistamab Receives Breakthrough Therapy Designation for Resistant Myeloma
ASCO 2021: EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer
AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer
ASCO 2021: INDUCE-1 Trial of Feladilimab Plus Pembrolizumab in Urothelial Carcinoma
EHA2021: Targeting BCMA in Early-Phase Study in Resistant Myeloma
ASCO 2021: Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML
ASCO 2021: Combination of HDAC Inhibitor and Pembrolizumab in Advanced Skin Cancer
ASCO 2021: Durvalumab-Based Therapy for Ultra-High–Risk Newly Diagnosed Myeloma
ASCO 2021: Neoadjuvant Therapy and Transurethral Resection of Bladder Cancer
ASCO 2021: 4-Year Update of ELEVATE-TN Trial of Acalabrutinib Regimens in CLL
Is KRAS Status Linked to Response to Immunotherapy for Advanced Lung Cancer?
ASCO 2021: Post Hoc Subgroup Analyses With Avelumab in Advanced Urothelial Carcinoma
ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma
ASCO 2021: Adjuvant Durvalumab Treatment for Triple-Negative Breast Cancer
EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma
ASCO 2021: Cemiplimab-rwlc and Quality of Life in Patients With Locally Advanced Skin Cancer
ASCO 2021: Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma
ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer
ASCO 2021: Can Live Bacterial Product Enhance Response to Immunotherapy in Metastatic Renal Cell Cancer?
EHA2021: Phase III GLOW Trial of Ibrutinib and Venetoclax as First-Line CLL Therapy
EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma
ASCO 2021: KEYNOTE-052 Survival Update on First-Line Pembrolizumab in Advanced Urothelial Cancer
ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma
ASCO 2021: Health-Related Quality of Life With Pembrolizumab for Cutaneous Squamous Cell Carcinoma
ASCO 2021: Bladder-Sparing Combination Therapy Under Study in Muscle-Invasive Urothelial Cancer
ASCO 2021: 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer
ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer
Australian Researchers Explore Immunotherapy-Related Concepts in Squamous Cell Skin Cancer
ASCO 2021: Surgical Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.